Medicine · 2016 · 32 citations · 15 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyUrologic OncologyBladder CancerChemotherapy Toxicity ManagementCombination ChemotherapyCytotoxic ChemotherapyGenitourinary Cancer PharmacotherapyAnticancer ChemotherapyChemotherapy-induced FatigueComplete Response AssessmentCyclophosphamide-based TherapyMetastatic Bladder CancerPlatinum-based AgentsRecist CriteriaSingle-agent Chemotherapy
Bladder cancer is a major cause of cancer-related mortality, with an estimated 74,000 new cases and 16,000 deaths in the United States in 2015. In patients with metastatic disease, vinflunine and taxanes are the most widely used chemotherapy agents in the second-line setting after failure of platinum-based treatment. Cyclophosphamide has been used in combination with paclitaxel in urothelial carcinoma of the bladder, but there are no data about the effectiveness of cyclophosphamide administered as a single agent.We here describe the first case of an advanced bladder cancer patient suffering from grade 2 fatigue.He benefited from administration of third-line single-agent metronomic oral cyclophosphamide plus oral doses of quercetin. A complete, prolonged radiologic response according to the RECIST criteria 1.1 was achieved with minimal toxicity and an improvement in fatigue.Further studies are required to assess the potential benefits associated with the combined use of cyclophosphamide plus quercetin in advanced bladder cancer patients.
15
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles, Joseph P. Eder, Gregg Fine et al. · Nature · 2014 · 2.4K citations
Medicine, Oncology, Pharmacology +12
Hans von der Maase, Lisa Sengeløv, J.T. Roberts et al. · Journal of Clinical Oncology · 2005 · 1.9K citations
Joaquim Bellmunt, Christine Théodore, T. Demkov et al. · Journal of Clinical Oncology · 2009 · 779 citations · Full text
Medicine, Oncology, Pharmacotherapy +10